INFEX Therapeutics
Joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | £2.3m | Early VC | |
| Total Funding | 000k | ||
Related Content
AMR Centre, operating in the biotechnology sector, focuses on developing innovative anti-infective therapeutics to combat drug-resistant infections. The company collaborates with various organizations to address the global health crisis posed by antimicrobial resistance (AMR). AMR Centre serves pharmaceutical companies, healthcare providers, and research institutions, primarily targeting the infectious disease market. Its business model revolves around research and development partnerships, licensing agreements, and co-development deals. Revenue is generated through milestone payments, royalties, and funding from collaborative projects. The company leverages its expertise and infrastructure to accelerate the development of new drugs, aiming to reduce the mortality rate associated with drug-resistant infections.
Keywords: antimicrobial resistance, drug development, biotechnology, infectious diseases, partnerships, therapeutics, superbugs, healthcare, licensing, research.